Charles River Laboratories stock dropped 41.6% from 52-week high, underperforming S&P 500

From Yahoo Finance: 2025-06-25 11:34:00

Charles River Laboratories International, Inc. is valued at $7.3 billion, providing drug discovery and safety testing services globally. Their stock has dropped 41.6% from its 52-week high, underperforming the S&P 500. Despite this, CRL saw an 18.7% jump following better-than-expected Q1 2025 earnings, with an improved operating margin and raised EPS guidance.

Analysts remain moderately optimistic about CRL, giving it a consensus rating of “Moderate Buy.” Despite underperformance, the stock is trading below the mean price target of $158.64. In comparison, Labcorp Holdings Inc. has surpassed CRL, with shares soaring 14.5% YTD and 26.2% over the past 52 weeks.



Read more at Yahoo Finance: Is Charles River Laboratories Stock Underperforming the S&P 500?